Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Other financing activities (2020 - 2024)

RxSight's Other financing activities history spans 5 years, with the latest figure at -$768000.0 for Q4 2024.

  • For Q4 2024, Other financing activities fell 7081.82% year-over-year to -$768000.0; the TTM value through Dec 2025 reached -$377000.0, changed N/A, while the annual FY2023 figure was $2.2 million, 1441.38% up from the prior year.
  • Other financing activities reached -$768000.0 in Q4 2024 per RXST's latest filing, down from $391000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.6 million in Q3 2023 to a low of -$768000.0 in Q4 2024.
  • Average Other financing activities over 5 years is $204466.7, with a median of $142000.0 recorded in 2022.
  • Peak YoY movement for Other financing activities: soared 960.13% in 2023, then crashed 7081.82% in 2024.
  • A 5-year view of Other financing activities shows it stood at $687000.0 in 2020, then plummeted by 135.23% to -$242000.0 in 2021, then skyrocketed by 38.02% to -$150000.0 in 2022, then surged by 107.33% to $11000.0 in 2023, then plummeted by 7081.82% to -$768000.0 in 2024.
  • Per Business Quant, the three most recent readings for RXST's Other financing activities are -$768000.0 (Q4 2024), $391000.0 (Q3 2024), and $377000.0 (Q2 2024).